ATA3219: Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies Built on Our EBV T-Cell Platform
- Academic program generated a proof-of-principle for EBV T-cell platform demonstrating the potential to generate off-the-shelf, allogeneic CAR T immunotherapies.
- ATA3219: Atara's next-generation, off-the-shelf, allogeneic EBV+ CD19-1XX CAR T-cell immunotherapy containing a modified CD3z signaling domain, 1XX.
Allogeneic CAR T targeting CD19, currently in clinical development, leverages our EBV T-cell platform and features a next-generation 1XX co-stimulatory domain.
- Phase 1
- Phase 2
- Phase 3
- Target: CD19
- Technologies: Novel CAR T 1XX co-stimulation
- Off-the-shelf, allogeneic
Next-Generation CAR T Technology
Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.